Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.73 |
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | NT5E | P21589 | 2/20 | 0.73 |
| ▸ | TOP2A | P11388 | 2/20 | 0.73 |
| ▸ | RELA | Q04206 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 2/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.67 |
| ▸ | RORC | P51449 | 2/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | GLI1 | P08151 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.67 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573802 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL16983599 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL15120375 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL13098063 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL2733084 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL214201 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL6112842 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL16994315 | 0.93 | PTPN1 (0.76) | PTPN1USP2LMNAHIF1ANT5E | |
| Water SCHEMBL8586171 | 0.92 | PTPN1 (0.75) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL8585647 | 0.90 | PTPN1 (0.75) | PTPN1USP2LMNAHIF1ANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088757-B2 | Betulinol derivatives as anti-cancer agents | BIORINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8008280-B2 | Betulinol derivatives as anti-HIV agents | BIORINGS LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | SAXENA RESEARCH, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | SAXENA RESEARCH, LLC | 2008-11-20 | — | — | US | disclosed |
| EP-1786433-A4 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | SAXENA BRIJ B (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1802648-A2 | BETULINOL DERIVATIVES AS ANTI-CANCER AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1786433-A2 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060154903-A1 | Betulinol derivatives as anti-cancer agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| US-20060154904-A1 | Betulinol derivatives as anti-HIV agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006031756-A2 | BETULINOL DERIVATIVES AS ANTI-CANCER AGENTS | CORNELL RESEARCH FOUNDATION, INC (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006031706-A2 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | CORNELL RESEARCH FOUNDATION, INC (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | PTPN1 4631/4885USP2 4167/4885LMNA 3645/4885 |
| US-20060154903-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | PTPN1 4559/4885USP2 4083/4885LMNA 3887/4885 |
| US-20060154904-A1 | Betulinol derivatives as anti-HIV agents | BET1, NFATC1, CD4 | PTPN1 1987/4885USP2 4717/4885LMNA 4335/4885 |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | BET1, NFATC1, CD4 | PTPN1 1987/4885USP2 4717/4885LMNA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.